{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:24:00Z","timestamp":1773887040157,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013003","name":"Universit\u00e0 degli Studi di Cagliari","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40259-021-00467-w","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T13:13:10Z","timestamp":1613740390000},"page":"175-186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6953-3508","authenticated-orcid":false,"given":"Elisabetta","family":"Chessa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1126-8315","authenticated-orcid":false,"given":"Matteo","family":"Piga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-0576","authenticated-orcid":false,"given":"Alberto","family":"Floris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0945-9518","authenticated-orcid":false,"given":"Mattia","family":"Congia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9426-7798","authenticated-orcid":false,"given":"Ignazio","family":"Cangemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5682-8227","authenticated-orcid":false,"given":"Alessandro","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7955-6786","authenticated-orcid":false,"given":"Alberto","family":"Cauli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"467_CR1","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","volume":"79","author":"A Sepriano","year":"2020","unstructured":"Sepriano A, Kerschbaumer A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2020;79:760\u201370. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216653.","journal-title":"Ann Rheum Dis"},{"key":"467_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","journal-title":"Ann Rheum Dis"},{"key":"467_CR3","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159.","journal-title":"Ann Rheum Dis"},{"key":"467_CR4","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, den Bosch FV, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76:978\u201391. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770.","journal-title":"Ann Rheum Dis"},{"key":"467_CR5","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736\u201345. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215089.","journal-title":"Ann Rheum Dis"},{"key":"467_CR6","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA. 2018;320:1360\u201372. https:\/\/doi.org\/10.1001\/jama.2018.13103.","journal-title":"JAMA"},{"key":"467_CR7","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1080\/14656566.2019.1617853","volume":"20","author":"E Toussirot","year":"2019","unstructured":"Toussirot E. Pharmacological management of axial spondyloarthritis in adults. Expert Opin Pharmacother. 2019;20:1483\u201391. https:\/\/doi.org\/10.1080\/14656566.2019.1617853.","journal-title":"Expert Opin Pharmacother"},{"key":"467_CR8","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","volume":"393","author":"T D\u00f6rner","year":"2019","unstructured":"D\u00f6rner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet. 2019;393:2344\u201358. https:\/\/doi.org\/10.1016\/S0140-6736(19)30546-X.","journal-title":"Lancet"},{"key":"467_CR9","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1016\/S0140-6736(19)32681-9","volume":"394","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou MG. JAK inhibitors: promising for a wider spectrum of autoimmune diseases? Lancet. 2019;394:2047\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(19)32681-9.","journal-title":"Lancet"},{"key":"467_CR10","doi-asserted-by":"publisher","first-page":"e0119683","DOI":"10.1371\/journal.pone.0119683","volume":"10","author":"JT Joensuu","year":"2015","unstructured":"Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordstr\u00f6m D, Blom M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS ONE. 2015;10:e0119683. https:\/\/doi.org\/10.1371\/journal.pone.0119683.","journal-title":"PLoS ONE"},{"key":"467_CR11","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2215\/CJN.01010115","volume":"10","author":"J Radhakrishnan","year":"2015","unstructured":"Radhakrishnan J, Perazella MA. Drug-induced glomerular disease: attention required! Clin J Am Soc Nephrol. 2015;10:1287\u201390. https:\/\/doi.org\/10.2215\/CJN.01010115.","journal-title":"Clin J Am Soc Nephrol"},{"key":"467_CR12","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1111\/bcp.14015","volume":"85","author":"R Ferner","year":"2019","unstructured":"Ferner R, Aronson J. Susceptibility to adverse drug reactions. Br J Clin Pharmacol. 2019;85:2205\u201312. https:\/\/doi.org\/10.1111\/bcp.14015.","journal-title":"Br J Clin Pharmacol"},{"key":"467_CR13","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1093\/rheumatology\/kex434","volume":"57","author":"M Jani","year":"2018","unstructured":"Jani M, Dixon WG, Chinoy H. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. Rheumatol (Oxf). 2018;57:1896\u2013907. https:\/\/doi.org\/10.1093\/rheumatology\/kex434.","journal-title":"Rheumatol (Oxf)"},{"key":"467_CR14","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.autrev.2014.05.005","volume":"13","author":"M Piga","year":"2014","unstructured":"Piga M, Chessa E, Ibba V, Mura V, Floris A, Cauli A, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev. 2014;13:873\u20139. https:\/\/doi.org\/10.1016\/j.autrev.2014.05.005.","journal-title":"Autoimmun Rev"},{"key":"467_CR15","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.2215\/CJN.01910215","volume":"10","author":"JJ Hogan","year":"2015","unstructured":"Hogan JJ, Markowitz GS, Radhakrishnan J. Drug-induced glomerular disease: immune-mediated injury. Clin J Am Soc Nephrol. 2015;10:1300\u201310. https:\/\/doi.org\/10.2215\/CJN.01910215.","journal-title":"Clin J Am Soc Nephrol"},{"key":"467_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135.","journal-title":"Ann Intern Med"},{"key":"467_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2008.04.019","volume":"20","author":"HS Rehan","year":"2009","unstructured":"Rehan HS, Chopra D, Kakkar AK. Physician\u2019s guide to pharmacovigilance: terminology and causality assessment. Eur J Intern Med. 2009;20:3\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2008.04.019.","journal-title":"Eur J Intern Med"},{"key":"467_CR18","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.2169\/internalmedicine.2640-19","volume":"58","author":"K Karasawa","year":"2019","unstructured":"Karasawa K, Iwabuchi Y, Kyoda M, Akihisa T, Yamaguchi E, Suzuki S, et al. Primary IgA vasculitis with nephritis in a patient with rheumatoid arthritis diagnosed by anti-galactose-deficient IgA1 immunostaining. Intern Med. 2019;58:2551\u20134. https:\/\/doi.org\/10.2169\/internalmedicine.2640-19.","journal-title":"Intern Med"},{"key":"467_CR19","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1111\/1756-185X.12612","volume":"20","author":"AM Alkhunaizi","year":"2017","unstructured":"Alkhunaizi AM, Dawamneh MF. ANCA-positive crescentic glomerulonephritis in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor alpha. Int J Rheum Dis. 2017;20:1843\u20137. https:\/\/doi.org\/10.1111\/1756-185X.12612.","journal-title":"Int J Rheum Dis"},{"key":"467_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.15171\/jnp.2017.10","volume":"6","author":"M G\u00f3is","year":"2017","unstructured":"G\u00f3is M, Messias A, Carvalho D, Carvalho F, Sousa H, Sousa J, et al. MPO-ANCA-associated necrotizing glomerulonephritis in rheumatoid arthritis; a case report and review of literature. J Nephropathol. 2017;6:58\u201362. https:\/\/doi.org\/10.15171\/jnp.2017.10.","journal-title":"J Nephropathol"},{"key":"467_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2169\/internalmedicine.3668-19","volume":"59","author":"I Itoh","year":"2020","unstructured":"Itoh I, Kasuno K, Yamamoto C, Takahashi N, Shimizu H, Ojima T, et al. IgA vasculitis developed as an adverse effect of tofacitinib taken for rheumatoid arthritis. Intern Med. 2020;59:817\u201321. https:\/\/doi.org\/10.2169\/internalmedicine.3668-19.","journal-title":"Intern Med"},{"issue":"6","key":"467_CR22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3899\/jrheum.190076","volume":"47","author":"AC Desbois","year":"2020","unstructured":"Desbois AC, Biard L, S\u00e8ne D, Brocheriou I, Rouvier P, Lioger B, et al. Rituximab-associated vasculitis flare: incidence, predictors, and outcome. J Rheumatol. 2020;47(6):896\u2013902. https:\/\/doi.org\/10.3899\/jrheum.190076 ((Epub 2019 Aug 1 PMID: 31371658)).","journal-title":"J Rheumatol."},{"key":"467_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00296-019-04241-8","volume":"39","author":"H Yarkan Tu\u011fsal","year":"2019","unstructured":"Yarkan Tu\u011fsal H, Zengin B, Kenar G, Can G, \u00dcnl\u00fc M, \u00d6nen F, et al. Infliximab-associated focal segmental glomerulosclerosis in a patient with ankylosing spondylitis. Rheumatol Int. 2019;39:561\u20137. https:\/\/doi.org\/10.1007\/s00296-019-04241-8.","journal-title":"Rheumatol Int"},{"key":"467_CR24","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.3899\/jrheum.160147","volume":"43","author":"RR Butendieck","year":"2016","unstructured":"Butendieck RR, Bhattacharya T, Geiger X. Development of nephrotic syndrome in a patient with rheumatoid arthritis treated with certolizumab. J Rheumatol. 2016;43:1770\u20132. https:\/\/doi.org\/10.3899\/jrheum.160147.","journal-title":"J Rheumatol"},{"key":"467_CR25","first-page":"1122","volume":"34","author":"Y Asami","year":"2016","unstructured":"Asami Y, Ishiguro H, Ueda A, Nakajima H. First report of membranous nephropathy and systemic lupus erythematosus associated with abatacept in rheumatoid arthritis. Clin Exp Rheumatol. 2016;34:1122.","journal-title":"Clin Exp Rheumatol"},{"key":"467_CR26","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.4103\/0366-6999.164992","volume":"128","author":"X Li","year":"2015","unstructured":"Li X, Ma J, Zhao Y, Wang H-Y, Li X-M. Development of crescentic immunoglobulin A nephritis and multiple autoantibodies in a patient during adalimumab treatment for rheumatoid arthritis. Chin Med J (Engl). 2015;128:2555\u20136. https:\/\/doi.org\/10.4103\/0366-6999.164992.","journal-title":"Chin Med J (Engl)"},{"key":"467_CR27","first-page":"683","volume":"36","author":"T Watanabe","year":"2018","unstructured":"Watanabe T, Hattori T, Ogawa Y, Jodo S. Successful treatment with tofacitinib for renal disorder due to amyloid A amyloidosis and immunoglobulin A nephropathy in a patient with rheumatoid arthritis. Clin Exp Rheumatol. 2018;36:683\u20134.","journal-title":"Clin Exp Rheumatol"},{"key":"467_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-020-00478-6","author":"D Fukaya","year":"2020","unstructured":"Fukaya D, Inoue T, Kogure Y, Kajiyama H, Ishizawa K, Seto T, et al. Tocilizumab-induced immunocomplex glomerulonephritis: a report of two cases. CEN Case Rep. 2020. https:\/\/doi.org\/10.1007\/s13730-020-00478-6.","journal-title":"CEN Case Rep"},{"key":"467_CR29","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.semarthrit.2016.09.006","volume":"46","author":"C Staveri","year":"2017","unstructured":"Staveri C, Karokis D, Liossis SNC. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab. Semin Arthritis Rheum. 2017;46:788\u201390. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.09.006.","journal-title":"Semin Arthritis Rheum"},{"key":"467_CR30","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/0961203316662724","volume":"26","author":"Y Saka","year":"2017","unstructured":"Saka Y, Taniguchi Y, Nagahara Y, Yamashita R, Karasawa M, Naruse T, et al. Rapidly progressive lupus nephritis associated with golimumab in a patient with systemic lupus erythematosus and rheumatoid arthritis. Lupus. 2017;26:447\u20138. https:\/\/doi.org\/10.1177\/0961203316662724.","journal-title":"Lupus"},{"key":"467_CR31","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1177\/0961203316641768","volume":"25","author":"S Manou-Stathopoulou","year":"2016","unstructured":"Manou-Stathopoulou S, Robson MG. Risk of clinical deterioration in patients with lupus nephritis receiving rituximab. Lupus. 2016;25:1299\u2013306. https:\/\/doi.org\/10.1177\/0961203316641768.","journal-title":"Lupus"},{"key":"467_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3109\/03009742.2014.887769","volume":"43","author":"C Sj\u00f6wall","year":"2014","unstructured":"Sj\u00f6wall C, C\u00f6ster L. Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity. Scand J Rheumatol. 2014;43:428\u201330. https:\/\/doi.org\/10.3109\/03009742.2014.887769.","journal-title":"Scand J Rheumatol"},{"key":"467_CR33","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.jdcr.2019.05.022","volume":"5","author":"A Al Khalili","year":"2019","unstructured":"Al Khalili A, Scott L, Dutz JP. New-onset autoantibody-mediated nephritis during ustekinumab therapy for psoriasis in patients with and without prior systemic lupus erythematosus. JAAD Case Rep. 2019;5:682\u20135. https:\/\/doi.org\/10.1016\/j.jdcr.2019.05.022.","journal-title":"JAAD Case Rep"},{"key":"467_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaci.2015.10.023","volume":"137","author":"M Her","year":"2016","unstructured":"Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137:19\u201327. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.023.","journal-title":"J Allergy Clin Immunol"},{"key":"467_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","volume":"25","author":"R Perez-Alvarez","year":"2013","unstructured":"Perez-Alvarez R, P\u00e9rez-de-Lis M, Ramos-Casals M. BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol. 2013;25:56\u201364. https:\/\/doi.org\/10.1097\/BOR.0b013e32835b1366.","journal-title":"Curr Opin Rheumatol"},{"key":"467_CR36","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1080\/14740338.2017.1372421","volume":"16","author":"M P\u00e9rez-De-Lis","year":"2017","unstructured":"P\u00e9rez-De-Lis M, Retamozo S, Flores-Ch\u00e1vez A, Kostov B, Perez-Alvarez R, Brito-Zer\u00f3n P, et al. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opin Drug Saf. 2017;16:1255\u201371. https:\/\/doi.org\/10.1080\/14740338.2017.1372421.","journal-title":"Expert Opin Drug Saf"},{"key":"467_CR37","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.3346\/jkms.2018.33.e188","volume":"33","author":"S-K Kim","year":"2018","unstructured":"Kim S-K, Choe J-Y. Gender is a risk factor for annual decline in estimated glomerular filtration rate in patients treated with biological DMARDs in rheumatoid arthritis and ankylosing spondylitis: a retrospective observational study. J Korean Med Sci. 2018;33:e188. https:\/\/doi.org\/10.3346\/jkms.2018.33.e188.","journal-title":"J Korean Med Sci"},{"key":"467_CR38","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2018-214598","volume":"78","author":"L Arnaud","year":"2019","unstructured":"Arnaud L, Mertz P, Gavand P-E, Martin T, Chasset F, Tebacher-Alt M, et al. Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database. Ann Rheum Dis. 2019;78:504\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214598.","journal-title":"Ann Rheum Dis"},{"key":"467_CR39","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/1744666X.2018.1468753","volume":"14","author":"W-H Boehncke","year":"2018","unstructured":"Boehncke W-H, Brembilla NC. Immunogenicity of biologic therapies: causes and consequences. Expert Rev Clin Immunol. 2018;14:513\u201323. https:\/\/doi.org\/10.1080\/1744666X.2018.1468753.","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"467_CR40","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.autrev.2017.10.009","volume":"16","author":"MH Heineke","year":"2017","unstructured":"Heineke MH, Ballering AV, Jamin A, et al. New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Sch\u00f6nlein purpura). Autoimmun Rev. 2017;16(12):1246\u201353. https:\/\/doi.org\/10.1016\/j.autrev.2017.10.009.","journal-title":"Autoimmun Rev"},{"key":"467_CR41","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/nrrheum.2011.35","volume":"7","author":"JC Prinz","year":"2011","unstructured":"Prinz JC. Autoimmune-like syndromes during TNF blockade: does infection have a role? Nat Rev Rheumatol. 2011;7:429\u201334. https:\/\/doi.org\/10.1038\/nrrheum.2011.35.","journal-title":"Nat Rev Rheumatol"},{"key":"467_CR42","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jbspin.2013.05.003","volume":"80","author":"M Michel","year":"2013","unstructured":"Michel M, Henri P, Vincent FB, Leon N, Marcelli C. Mesangial immunoglobulin (Ig)A glomerulonephritis in a patient with rheumatoid arthritis treated with abatacept. Joint Bone Spine. 2013;80:660\u20133. https:\/\/doi.org\/10.1016\/j.jbspin.2013.05.003.","journal-title":"Joint Bone Spine"},{"key":"467_CR43","doi-asserted-by":"publisher","first-page":"keaa796","DOI":"10.1093\/rheumatology\/keaa796","volume":"20","author":"I Parodis","year":"2020","unstructured":"Parodis I, Vital EM, Hassan SU, J\u00f6nsen A, Bengtsson AA, Eriksson P, et al. De novo lupus nephritis during treatment with belimumab. Rheumatol (Oxf). 2020;20:keaa796. https:\/\/doi.org\/10.1093\/rheumatology\/keaa796.","journal-title":"Rheumatol (Oxf)"},{"key":"467_CR44","unstructured":"Arango M-T, Shoenfeld Y, Cervera R, Anaya J-M. Infection and autoimmune diseases [Internet]. autoimmunity: from bench to bedside [Internet]. El Rosario University Press. 2013. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459437\/. Accessed 21 Jun 2020."},{"key":"467_CR45","unstructured":"The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. 2019. https:\/\/www.who.int\/medicines\/areas\/quality_safety\/safety_efficacy\/WHOcausality_assessment.pdf. Accessed 30 May 2020."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00467-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-021-00467-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-021-00467-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T11:09:00Z","timestamp":1617880140000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-021-00467-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1007\/s40259-021-00467-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"16 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Cagliari within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AC has received consulting fees or honorarium for lectures or travel grants from Pfizer, BMS, Lilly, Janssen, Celgene, AbbVie, Novartis and MSD. EC, MP, AF, MC, IC and AM have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MP, EC and AM contributed to the study conception and design. Material preparation, data collection and analysis were performed by MP and EC. AAC, AF, MC, IC and AM commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}